Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Antonelli, L; Heidenreich, A; Bagrodia, A; Amini, A; Baky, F; Branger, N; Cazzaniga, W; Clinton, TN; Daneshmand, S; Djaladat, H; Eggener, S; Ghoreifi, A; Hamilton, RJ; Ho, M; Sexton, WJ; Nazzani, S; Nicol, D; Nicolai, N; Olson, K; Paffenholz, P; Porter, J; Qian, Z; Rocco, NR; Yerrapragada, A; Stroup, SP; Tachibana, I; Terbuch, A; Singla, N; Cary, C; Fankhauser, CD, , EAU‐YAU, Penile, and, Testis, Cancer, Working, Group.
Primary retroperitoneal lymph node dissection in clinical stage 2a/b non-seminomatous germ cell tumour.
BJU Int. 2024; Doi: 10.1111/bju.16618
Web of Science PubMed FullText FullText_MUG

Co-authors Med Uni Graz: Terbuch Angelika
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: OBJECTIVES: To reassess the role of primary retroperitoneal lymph node dissection (RPLND) in patients with marker-negative non-seminomatous germ cell tumour (NSGCT) clinical stage (CS) 2a, to explore results in patients with CS 2b and to evaluate surgical methods, recurrence, and adjuvant chemotherapy indications. MATERIALS AND METHODS: Data from 17 institutions were collected, comprising 305 men who underwent primary RPLND for CS 2 NSGCT. Regression analyses were conducted to predict histology in the RPLND specimen and disease-free survival (DFS). RESULTS: A larger retroperitoneal lymph node diameter was associated with pure teratoma in the RPLND specimen (odds ratio [OR] 1.02, 95% confidence interval [CI] 1.01-1.07; P = 0.03), but no association was observed with DFS. The 5-year DFS rates in marker negative CS 2a and 2b were 79% and 76%. In men with non-teratomatous viable cancer in the RPLND specimen, the 5-year DFS rates for CS 2a and 2b were 95% and 87% with adjuvant chemotherapy, and 67% and 74% without adjuvant chemotherapy. We did not identify an association between the number of adjuvant chemotherapy cycles and DFS. CONCLUSIONS: Our study suggests considering primary RPLND not only in marker-negative CS 2a but also in CS 2b. Further research should determine the efficacy of primary RPLND in men with CS 2c and marker-positive CS 2, as well as which patients may benefit from adjuvant chemotherapy and the optimal cycle number.
Find related publications in this database (Keywords): testis cancer; primary retroperitoneal lymph node dissection; adjuvant chemotherapy; viable germ cell tumour; non-seminomatous germ cell tumour